Patient enrollment underway in PROGRESS, a Phase 2b study of LX9211 in Diabetic Peripheral Neuropathic Pain; topline data anticipated Q2 2025 Preparations underway for Phase 3 study of sotagliflozin ...
THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する